Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 16, 2005. The report details a specific corporate action regarding the repurchase of the company's own shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 25, 2005.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 370,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,334.08 pence per share.
- Treasury Holdings: 98,653,000 shares held in Treasury following the transaction.
- Shares in Issue: 5,846,694,217 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company acquired 370,000 shares on June 16, 2005, which were subsequently placed in Treasury. No other material changes to operations or financial position are detailed in this specific filing.
Guidance, Outlook, and Risks
This filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. The document is strictly a notification of a share repurchase event.
Investor Verification Points
- Verify the total cost of the 370,000 shares purchased at 1,334.08 pence per share.
- Confirm the updated total number of shares in issue (5,846,694,217) against subsequent filings.
- Review the Annual General Meeting minutes from May 25, 2005, to understand the full scope of the share buyback authority granted.